Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice

Wenwen Yue, Liang Chen, Luodan Yu, Bangguo Zhou, Haohao Yin, Weiwei Ren, Chang Liu, Lehang Guo, Yifeng Zhang, Liping Sun, Kun Zhang (), Huixiong Xu () and Yu Chen ()
Additional contact information
Wenwen Yue: Tongji University School of Medicine
Liang Chen: Tongji University School of Medicine
Luodan Yu: Shanghai Institute of Ceramics, Chinese Academy of Sciences
Bangguo Zhou: Tongji University School of Medicine
Haohao Yin: Tongji University School of Medicine
Weiwei Ren: Tongji University School of Medicine
Chang Liu: Tongji University School of Medicine
Lehang Guo: Tongji University School of Medicine
Yifeng Zhang: Tongji University School of Medicine
Liping Sun: Tongji University School of Medicine
Kun Zhang: Tongji University School of Medicine
Huixiong Xu: Tongji University School of Medicine
Yu Chen: Shanghai Institute of Ceramics, Chinese Academy of Sciences

Nature Communications, 2019, vol. 10, issue 1, 1-15

Abstract: Abstract Combined checkpoint blockade (e.g., PD1/PD-L1) with traditional clinical therapies can be hampered by side effects and low tumour-therapeutic outcome, hindering broad clinical translation. Here we report a combined tumour-therapeutic modality based on integrating nanosonosensitizers-augmented noninvasive sonodynamic therapy (SDT) with checkpoint-blockade immunotherapy. All components of the nanosonosensitizers (HMME/R837@Lip) are clinically approved, wherein liposomes act as carriers to co-encapsulate sonosensitizers (hematoporphyrin monomethyl ether (HMME)) and immune adjuvant (imiquimod (R837)). Using multiple tumour models, we demonstrate that combining nanosonosensitizers-augmented SDT with anti-PD-L1 induces an anti-tumour response, which not only arrests primary tumour progression, but also prevents lung metastasis. Furthermore, the combined treatment strategy offers a long-term immunological memory function, which can protect against tumour rechallenge after elimination of the initial tumours. Therefore, this work represents a proof-of-concept combinatorial tumour therapeutics based on noninvasive tumours-therapeutic modality with immunotherapy.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-09760-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09760-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-09760-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().